Dear readers,
Welcome to our report on the latest advancements in stem cell research. Within these pages, you’ll explore the transformative potential of stem cell therapies in treating chronic diseases and cancer, and advancing regenerative medicine.
We cover a wide range of developments, including stromal vascular fraction (SVF) therapy for osteoarthritis, and the pioneering research from organisations such as Enthera Pharmaceuticals and Immorta Bio. These companies are leading the way in developing treatments for type 1 diabetes, inflammatory bowel disease, and age-related conditions. Additionally, we examine the growing potential of placenta-derived stem cells in treating cancer and chronic diseases, along with other innovative approaches that are pushing the boundaries of regenerative medicine.
Featured experts:
- Dr Vasiliki E Kalodimou, Assistant Professor of Biology at the European University-Cyprus
- Dr Lisa Maria Olson, CEO of Enthera Pharmaceuticals
- Dr Robert Hariri, Founder, Chairman and CEO of Celularity
- Dr Thomas Ichim, President and Chief Scientific Officer of Immorta Bio
- Prof Alan Trounson, CEO & Executive Director of Cartherics
- Frank Gleeson, Co-founder and CEO of Satellos Bioscience
This report also highlights the significant contributions of key leaders in the field, including Prof Alan Trounson’s pioneering work with immune stem cells and Satellos Bioscience’s innovative approach to Duchenne muscular dystrophy (DMD). These advancements demonstrate how stem cell-based therapies could redefine healthcare in the years ahead.
Sincerely,
Dr Carrie Haslam
Editor
Drug Target Review
